Dexamethasone marginally surpasses MSC-secretome in resolving acute liver failure in mice DOI Creative Commons
Thoria Diab, Eiman M. Adly, Mohamed Hessien

et al.

The Animal Biology, Journal Year: 2024, Volume and Issue: 26(4), P. 12 - 17

Published: Dec. 1, 2024

The anti-inflammatory roles of Mesenchymal stem cells (MSCs) and glucocorticoids are well-reported in both preclinical clinical studies. However, it is not clear how far MSC-secretome offers sufficient protection against acute liver failure (ALF) compared to glucocorticoids. To answer this query, was induced mice by a single toxic dose (400 mg/kg) acetaminophen (APAP). Then were treated with Dexamethasone or transfused MSC-secretome, which derived from DEX-treated bone marrow mesenchymal cells. results showed that 10 nM DEX has no impact on the viability characteristics MSCs. While transfusion provided significant therapeutic effect ALF, marginally less effective than treatment. Hepatic markers (ALT, ALP, GGT, bilirubin) improved more significantly group. This improvement accompanied marked relief oxidative assessed as Nrf-2, MDA, GSH. Additionally, normal levels angiogenic (VEGF), inflammatory (TNF-α) effectively restored after Also, resolved necrosis. In summary, these data suggest dexamethasone demonstrates better treatment ALF. Further studies necessary standardize an acellular approach.

Language: Английский

Cutting-edge insights into liver fibrosis: advanced therapeutic strategies and future perspectives using engineered mesenchymal stem cell-derived exosomes DOI Creative Commons
Manar A. Didamoony, Ayman A. Soubh, Lamiaa A. Ahmed

et al.

Drug Delivery and Translational Research, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 24, 2025

Abstract Liver fibrosis is still a serious health concern worldwide, and there increasing interest in mesenchymal stem cells (MSCs) with tremendous potential for treating this disease because of their regenerative paracrine effects. Recently, many researches have focused on using the released exosomes (EXOs) from to treat liver rather than parent themselves. MSC-derived EXOs (MSC-EXOs) demonstrated favourable outcomes similar cell treatment terms regenerative, immunomodulatory, anti-apoptotic, anti-oxidant, anti-necroptotic, anti-inflammatory anti-fibrotic actions several models fibrosis. are superior terms, including lower immunogenicity risk tumour formation. However, maintaining stability efficacy after vivo transplantation remains major challenge clinical applicability. Therefore, strategies been applied engineering, such as parental modification or modifying directly achieve optimum performance Herein, we discuss underlying mechanisms an overview available therapies, among them EXOs. We also summarise recent developments improving effectiveness advantages limitations these approaches upcoming applications. Graphical

Language: Английский

Citations

1
Hotspots and trends in stem cell therapy for liver fibrosis and cirrhosis: A bibliometric analysis DOI

Wenyan Zhu,

Xiangyang Li,

Jialing Xie

et al.

World Journal of Hepatology, Journal Year: 2025, Volume and Issue: 17(1)

Published: Jan. 6, 2025

Liver fibrosis and cirrhosis are global medical challenges that require safe effective treatments. In the past two decades, there has been a surge in research on stem cell therapy for liver cirrhosis. This study aimed to conduct comprehensive analysis of hotspots trends this field through bibliometrics. To bibliometric treatment Publications were retrieved from Web Science Core Collection database. The distribution collaboration among literature, authors, countries, institutions analyzed visually using Excel, CiteSpace, Bibliometrix R-package, VOSviewer Pajek software. Additionally, an investigation keywords, burst clusters was conducted. As September 20, 2024, total 1935 documents dating 2004 with 1186 strongly relevant publications obtained after screening. China, United States, Japan major contributors field. Cairo University, Zhejiang University Yamaguchi institution journal Stem Cell Research & Therapy published most papers. There 686 Shuji Terai, Isao Sakaida, Soon Koo Baik, Lanjuan Li publishing focused alcoholic nonalcoholic fatty disease. emerging areas interest extracellular vesicles, exosomes, their enriched microRNAs. is experiencing rapid growth due changing increasing literature. These findings provide thorough overview

Language: Английский

Citations

0
Exploring Extracellular Vesicles: A Novel Approach in Nonalcoholic Fatty Liver Disease DOI

Ana Isabel Vigil Medina,

Mengdie Shi,

Yanyan Wang

et al.

Journal of Agricultural and Food Chemistry, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 23, 2025

Nonalcoholic fatty liver disease (NAFLD) represents an increasing public health concern. The underlying pathophysiological mechanisms of NAFLD remains unclear, and as a result, there is currently no specific therapy for this condition. However, recent studies focus on extracellular vesicles (EVs) novelty in their role cellular communication. An imbalance the gut microbiota composition may contribute to progression NAFLD, making gut-liver axis promising target therapeutic strategies. This review aims provide comprehensive overview EVs NAFLD. Additionally, exosome-like nanovesicles derived from plants (PELNs) probiotics-derived (postbiotics) have demonstrated potential re-establish intestinal equilibrium modulate microbiota, thus offering alleviate via axis. Further research needed using multiple omics approaches comprehensively characterize cargo including protein, metabolites, genetic material packaged, biological activities diverse microbes plants.

Language: Английский

Citations

0
Exosomes: A Promising Drug Delivery Tool in Hepatic Drug Delivery DOI
Neha Kanojia,

Komal Thapa,

Thakur Gurjeet Singh

et al.

Journal of Drug Delivery Science and Technology, Journal Year: 2025, Volume and Issue: unknown, P. 106761 - 106761

Published: March 1, 2025

Language: Английский

Citations

0
Identification of CDK1 as a Biomarker for the Treatment of Liver Fibrosis and Hepatocellular Carcinoma Through Bioinformatics Analysis DOI Open Access

Jiayi Qin,

Zhuan Li

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(8), P. 3816 - 3816

Published: April 17, 2025

Cyclin-dependent kinase 1 (CDK1) has emerged as a critical regulator of cell cycle progression, yet its role in liver fibrosis-associated hepatocellular carcinoma (LF-HCC) remains underexplored. This study aimed to systematically evaluate CDK1’s prognostic significance, immune regulatory functions, and therapeutic potential LF-HCC pathogenesis. Integrated bioinformatics approaches were applied multi-omics datasets from GEO, TCGA, TIMER databases. Differentially expressed genes identified through enrichment analysis protein–protein interaction networks. Survival outcomes assessed via Kaplan–Meier analysis, while infiltration patterns quantified using CIBERSORT. Molecular docking simulations evaluated binding affinity with pharmacologically active compounds (alvocidib, seliciclib, alsterpaullone) AutoDock Vina. CDK1 demonstrated significant overexpression tissues compared normal controls (p < 0.001). Elevated expression correlated reduced overall survival (HR = 2.41, 95% CI:1.78–3.26, p 0.003) advanced tumor staging 0.007). Immune profiling revealed strong associations between levels immunosuppressive infiltration, particularly T cells (r 0.63, 0.001) myeloid-derived suppressor 0.58, 0.004). confirmed high-affinity inhibitors conserved hydrogen-bond interactions (binding energy ≤ −8.5 kcal/mol), alvocidib showing optimal stability. multimodal establishes both biomarker immunomodulatory The enzyme’s dual driving progression reshaping the microenvironment positions it promising target. Computational validation provides rational basis for developing precision therapies against LF-HCC, bridging translational gaps discovery clinical application.

Language: Английский

Citations

0
Recent advances in the delivery of microRNAs via exosomes derived from MSCs, and their role in regulation of ferroptosis DOI
Mohamed J. Saadh,

Hanan Hassan Ahmed,

Gaurav Sanghvi

et al.

Pathology - Research and Practice, Journal Year: 2025, Volume and Issue: unknown, P. 155984 - 155984

Published: April 1, 2025

Language: Английский

Citations

0
Molecular Mechanisms of Fibrosis in Cholestatic Liver Diseases and Regenerative Medicine-Based Therapies DOI Creative Commons
Weilu Wang,

Huibin Lian,

Yingyu Liang

et al.

Cells, Journal Year: 2024, Volume and Issue: 13(23), P. 1997 - 1997

Published: Dec. 3, 2024

The aim of this review is to explore the potential new regenerative medicine approaches in treatment cholestatic liver fibrosis. Cholestatic diseases, such as primary biliary cholangitis (PBC), sclerosing (PSC), and atresia (BA), due accumulation bile, often progress fibrosis, cirrhosis, failure. When disease becomes severe enough require transplantation. Deeply understanding disease's progression fibrosis formation crucial for better diagnosis treatment. Current treatments mainly target root causes no direct method itself. Recent advances offer a approach that may help find ways directly, offering hope improved outcomes. We also summarize, analyze, discuss current state benefits therapies mesenchymal stem cell (MSC) therapy, induced pluripotent cells (iPSCs), organoid technology, which diseases. Focusing on latest research reveal targets enhance therapeutic efficacy, potentially leading more effective management even curative strategies

Language: Английский

Citations

2
Extracellular Vesicles in Viral Liver Diseases DOI Creative Commons
Elias Kouroumalis, Ioannis Tsomidis, Argyro Voumvouraki

et al.

Viruses, Journal Year: 2024, Volume and Issue: 16(11), P. 1785 - 1785

Published: Nov. 17, 2024

Extracellular vesicles (EVs) are bilayer released by cells in the microenvironment of liver including parenchymal and non-parenchymal cells. They third important mechanism communications between cells, besides secretion cytokines chemokines direct cell-to-cell contact. The aim this review is to discuss role EVs viral disease, as there increasing evidence that transportation proteins, all types RNA, particles complete virions implicated pathogenesis both cirrhosis viral-related hepatocellular carcinoma. biogenesis discussed their diseases presented. Their use diagnostic prognostic biomarkers also analyzed. Most importantly, significance possible novel treatment strategies for fibrosis carcinoma presented, although available data based on experimental clinical trials have not been reported.

Language: Английский

Citations

0
Dexamethasone marginally surpasses MSC-secretome in resolving acute liver failure in mice DOI Creative Commons
Thoria Diab, Eiman M. Adly, Mohamed Hessien

et al.

The Animal Biology, Journal Year: 2024, Volume and Issue: 26(4), P. 12 - 17

Published: Dec. 1, 2024

The anti-inflammatory roles of Mesenchymal stem cells (MSCs) and glucocorticoids are well-reported in both preclinical clinical studies. However, it is not clear how far MSC-secretome offers sufficient protection against acute liver failure (ALF) compared to glucocorticoids. To answer this query, was induced mice by a single toxic dose (400 mg/kg) acetaminophen (APAP). Then were treated with Dexamethasone or transfused MSC-secretome, which derived from DEX-treated bone marrow mesenchymal cells. results showed that 10 nM DEX has no impact on the viability characteristics MSCs. While transfusion provided significant therapeutic effect ALF, marginally less effective than treatment. Hepatic markers (ALT, ALP, GGT, bilirubin) improved more significantly group. This improvement accompanied marked relief oxidative assessed as Nrf-2, MDA, GSH. Additionally, normal levels angiogenic (VEGF), inflammatory (TNF-α) effectively restored after Also, resolved necrosis. In summary, these data suggest dexamethasone demonstrates better treatment ALF. Further studies necessary standardize an acellular approach.

Language: Английский

Citations

0